



**R**evilico

# Meet Our Team



**Asiyah Awais**  
MTM



**Anthony Kim**  
MBA/MCS



**Aziz Kamoun**  
MBA/MEng



**Gracie Teed**  
MEng Bioengineering



**Liz Chendo**  
LLM

# Challenges Persist in Preclinical Drug Discovery



## Traditional:

- High drug development costs
- Long initial process times
- Limited compound screening

## AI-Enabled:

- Recursion & others have yet to bring one drug to market
- “Faster hits aren’t enough”

## Efficiency, effectiveness and productivity in pharmaceutical R&D

## The Reality of Drug Discovery and Development

Why drug development is slowing down – and what to do about it

Target-based Drug Discovery Is Inefficient: Discovery and “Off-target” Mechanisms of All Drugs

30 years is too long to wait for new medicines. There are ways to speed up drug development

How can prioritizing data accelerate drug discovery?

# How Did Drug Discovery Become So Slow?

Diagnosing the decline in pharmaceutical R&D efficiency


Can Government Or Industry Make Drug Discovery More Efficient?

The Challenge of Inefficiency in Drug Discovery

## Why Does Drug Development Take So Long?


The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements

# The Allure of the Large AI Drug Discovery Market...



Polaris Market Research. (n.d.). AI in drug discovery market share and forecast, 2025-2034. Polaris Market Research. Retrieved March 2, 2025, from <https://www.polarismarketresearch.com/industry-analysis/ai-in-drug-discovery-market>

# ...But Competition is Fierce





# Revilico: Redefining *In Silico* Drug Discovery

- IP-protected data aggregation infrastructure
- Virtualized cell platform
- Marketplace for **preferred CRO partners** for wet lab validation and data
- **Distinctive oncology** focus


The screenshot displays the Revilico web application interface. On the left is a navigation sidebar with a 'scRNAseq Analysis' menu containing options like 'Gene Expressions', 'Clustering Analysis' (highlighted in blue), 'scRNA Preprocessing', 'Data Extraction', 'Target Analysis', and 'Protein Atlas'. The main workspace is divided into a top instruction panel, a central configuration area, and a right-side 'Visualisation' panel. The configuration area includes fields for 'Individual File / Control File' (with a file named 'Control\_GSM8245469.h5ad'), 'Experimental File (optional)' (with 'Paclitaxel\_G...aclitaxel.h5ad'), a 'Select type of UMAP' dropdown set to '3D UMAP', and a 'Select Gene' dropdown set to 'EGFR'. Below these are sliders for 'Expression Level' (set to 70) and 'Marker Size' (set to 10). A prominent blue callout box with white text says 'Click Run to execute the clustering analysis with your current settings.' pointing to a blue 'Run' button at the bottom right. The bottom left corner shows a user account icon and the text 'US Account'.

# Value Capture Through Strategic Partners





# Vision for the Future: Virtual Cell Lines



- Model **biology** into preclinical phase
- Recapitulate **cells**, then **tissues**, and eventually full **organ** systems

# Meet the CSO and Co-Founder



**CHRISTIAN CHUNG**

# Thank You

---

